SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending due to strong community support and its association with the Solana ecosystem, with many highlighting the acronym's positive message: We're All Gonna Make It. Community members are actively promoting the coin's potential, emphasizing its strong cultural relevance and comparing it to previous meme coin successes like $SHIB and $DOGE.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to the announcement that its Black Widow drone system has been approved and added to the NATO Support and Procurement Agency catalog, a move seen as a significant step towards potential contracts and revenue. The community is actively discussing the implications of this approval, with some expressing optimism about future growth and others remaining cautious until actual purchase orders are secured. Broader discussions include comparisons to other drone companies and the potential impact on the defense sector.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending due to a recently announced $750 million ATM offering, which the community is interpreting in several ways: some believe it's a strategic move to fund acquisitions or secure large government contracts, while others worry about potential dilution and delayed timelines for the Neutron rocket; despite differing opinions, many view it as a sign of growth and opportunity, especially given the company's position in the expanding space sector.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is trending due to disappointing earnings, with revenue and EPS missing estimates, sparking discussions about its financial health. The community is focused on the potential for a continued downturn, while some are looking at its low price with high short interest and institutional ownership as an opportunity for a potential short squeeze. Broader concerns about consumer discretionary spending and the company's strategic direction are also being discussed.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid growing interest in nuclear energy's role in powering AI data centers, further fueled by a new facility announcement and positive analyst coverage. Community discussions revolve around the company's future growth potential versus valuation concerns, especially as it remains pre-revenue. The stock's volatile price action sparks debates on long-term prospects amid broader sector tailwinds.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending due to its acquisition of Titan Software Engineering, a move into the defense AI market, sparking community discussion around the company's strategic shift and potential growth; many traders are watching for a sustained breakout, while others express concerns about cash position and potential dilution. The stock's volatility and past pumps are also driving conversation as traders weigh the risks and opportunities.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as it approaches all-time highs, with community members closely watching for a breakout above the $97-$100 range. Bullish sentiment is fueled by the company's inclusion in the S&P 100, a recent investment from Lucid Motors, and expansion into new sectors like train travel and retail delivery, though some analysts cite concerns about labor regulations and competition from autonomous vehicles.

WEBTOON Entertainment, Inc. engages in the provision of global storytelling platform. The firm offers creators and users to discover, create, and share new content. Its brands include Munpia, Yonder, Studio Lico, LINE, and Creator Studios. The company was founded by Jun-Koo Kim in 2005 and is headquartered in Los Angeles, CA.

Webtoon Entertainment Inc.

Webtoon Entertainment Inc

Webtoon Entertainment is trending following news of a broadened relationship with Disney to create a new digital comics platform, leading to significant after-hours gains. Community discussions revolve around the potential competition with existing platforms like YouTube and the implications of Disney acquiring a small equity stake. Some traders are eyeing potential price targets, while others discuss shorting opportunities, highlighting the stock's volatility and the anime/digital comic sector's potential.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending as analysts debate the impact of its expansion into Asia amid concerns about high valuation and a potential consumer spending pullback. Community members are closely watching the stock's performance, with some expressing frustration over recent declines and service issues, while others see it as oversold and a potential buying opportunity. Discussions also involve comparisons to competitors and concerns about the CEO's strategy.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

LYFT is trending as the community discusses its recent price movement and potential catalysts. Bullish sentiment is fueled by factors like profitability, revenue growth, and possible acquisition, while some analysts point to a potential reduction in costs due to legislative changes as a driver.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR Capricor Therapeutics, Inc. Sued for Securities Law Violations...

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR Faruqi & Faruqi Reminds Capricor Investors of the Pending...

Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates

Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Equity

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

Capricor Therapeutics (CAPR) on Friday said the U.S. Food and Drug Administration (FDA) has refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.<a href="https://stocktwits.com/symbol/CAPR">CAPR shares</a> were trading 39% lower in the pre-market session.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on">told</a> Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data.Capricor said the health regulator also referenced certain outstanding items in the Chemistry, Manufacturing, and Controls (CMC) section of the application.The company said it plans to engage further with the FDA to determine the next appropriate steps.Capricor CEO Linda Marbán expressed surprise at the FDA’s decision, calling it “unexpected.” &nbsp;“We have followed their guidance throughout the process. Prior to the CRL (complete response letter), the review had advanced without major issues, including a successful pre-licensure inspection and completion of the mid-cycle review,” she said.The CEO added that the company plans to submit data from a late-stage trial of 104 patients to provide additional evidence of effectiveness. Results from the study are expected in the third quarter of 2025.“We believe these data, if positive, along with our existing long-term clinical results showing cardiac stabilization, preservation of skeletal muscle function, and a consistent safety profile, could support efforts to resolve the questions raised by the FDA for the treatment of cardiomyopathy associated with DMD,” she said.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD.DMD therapies have been under increased scrutiny since last month after the FDA <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">announced</a> it is investigating the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Sarepta Therapeutics’ (SRPT) FDA-approved gene therapy Elevidys.FDA is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys, and is evaluating the need for further regulatory action, the agency said.On Stocktwits, retail sentiment around Capricor remained unmoved within ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1364/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_8_36_02_AM_png_93fa8a7f51.webp" alt="CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits" width="1364" height="128"><figcaption>CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure> CAPR stock is down by 17% this year but up by over 148% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-recall-query-into-nearly-28000-polestar-2-vehicles/ch8c9BwR5Zd">US Regulator Opens Recall Query Into Nearly 28,000 Polestar 2 Vehicles, But Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy

The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data.

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results in multiple cohorts of its Phase 1b/2a BEACON study evaluating briquilimab for chronic spontaneous urticaria (CSU), a skin allergy.BMO Capital cut the stock to 'Market Perform' from 'Outperform' and slashed its price target to $4 from $15, citing uncertainty caused by manufacturing issues that made it “challenging to separate the signal from the noise.”Cantor Fitzgerald also downgraded the shares to 'Neutral' from 'Overweight', saying the update “introduced uncertainty for clinical trial execution and development timelines.”&nbsp;The firm said it would wait for clarity on future Phase 2b regimens and timelines before re-engaging.William Blair issued a similar downgrade to 'Market Perform' from 'Outperform', flagging a lack of clarity around funding and concerns over the inactive drug lot, which also led Jasper to halt briquilimab development in asthma.&nbsp;The company confirmed that the affected batch was used in all patients in its ETESIAN asthma study.BTIG reduced its price target to $20 from $64 but maintained a 'Buy' rating, calling briquilimab “safe and active” with “compelling efficacy,” despite the paused asthma trial and delayed Phase 2b CSU start, now expected mid-2026.H.C. Wainwright dropped its target to $20 from $40 and retained a 'Buy' rating, citing the “surprising update” on the affected cohorts.&nbsp;The research firm shifted U.S. launch estimates for CSU and chronic inducible urticaria to 2030 and 2031, respectively, and now models a $5 million capital raise.Jasper said the affected cohorts — 240 mg Q8W and 240 mg loading dose plus 180 mg Q8W — showed little to no clinical response, with 10 of 13 patients dosed from the compromised batch.&nbsp;The company plans to replace the products for those patients and enroll 10–12 more across both cohorts. New data is expected in the fourth quarter.Across other cohorts, briquilimab produced deep and durable disease control.&nbsp;In the 240 mg and 360 mg single-dose groups, 8 of 9 participants achieved a complete response, with strong reductions in UAS7 and tryptase levels.&nbsp;Results from the open-label extension study also showed promising efficacy.Jasper is halting asthma and SCID development and may restructure to cut costs and extend its runway.However, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/JSPR">Jasper Therapeutics</a> on Stocktwits was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Jasper looked oversold and predicted a move above $5, calling the reaction to the update an overreaction to 90% good news.<stembedurl>https://stocktwits.com/trt102967/message/620133879</stembedurl>Another user compared the situation to&nbsp;<a href="https://stocktwits.com/symbol/CAPR/news">Capricor Therapeutics</a> , which dropped last month after reports that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-slumps-on-report-of-key-fda-exec-removal/chlxVk2RRPt">two key FDA officials</a> overseeing the company’s cell therapy application were placed on administrative leave.<stembedurl>https://stocktwits.com/jlove0303/message/620128019</stembedurl>Jasper Therapeutics’ stock has declined 85.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jasper Therapeutics (JSPR) is investigating a compromised drug batch in its briquilimab skin allergy trial/ Photo credit: Getty Images

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee meeting regarding approval for its Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD) associated cardiomyopathy.Capricor shares were trading 19% higher at the time of writing.The FDA indicated that an advisory committee meeting is not required at this time, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/318/capricor-therapeutics-provides-regulatory-update-on">said</a>, while adding that its application for Deramiocel approval remains under priority review.The company said in May that the FDA is considering an advisory committee meeting, dragging down investor optimism for a possible approval.The agency is expected to decide on the approval of the drug by Aug. 31. &nbsp;Company CEO Linda Marbán said that all regulatory milestones to date have proceeded as expected, and no major issues were noted at the mid-cycle review of the application.An in-person late-cycle meeting is now scheduled for mid-July.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_58_45_PM_png_3f23c3492d.webp" alt="CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the drug getting approved early following the company’s update.<stembedurl>https://stocktwits.com/Drichman7/message/618833665</stembedurl>However, Roth Capital analyst Boobalan Pachaiyappan told investors in a research note that the FDA's intention not to require a meeting "at this time" for Deramiocel “may not necessarily be positive news.”The analyst believes a promissory advisory committee meeting would be positive, as a potential positive panel vote would put pressure on the new FDA leadership to approve deramiocel in its current form.The firm reiterates a ‘Buy’ rating and $31 price target on Capricor shares.H.C. Wainright, however, opined that even in bear case scenarios with the FDA, late-stage trial data readouts are "waiting in the wings" to further strengthen Deramiocel's overall clinical and regulatory package. The analyst believes Deramiocel's first-in-class therapeutic profile, in tandem with strong manufacturing support, will get the therapy over the finish line on expected timelines, as per TheFly.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 34% this year but up by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-presses-congress-to-pass-tax-bill-and-get-the-deal-done-this-week-after-iran-israel-ceasefire/chm4iPpRR3L">Trump Presses Congress To Pass Tax Bill And ‘Get The Deal Done’ This Week After Iran-Israel Ceasefire</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy have been placed on administrative leave.Stat News on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/06/18/top-gene-therapy-regulator-forced-out-at-fda/">reported</a>, citing a recording of a meeting, that Verdun and her deputy Rachael Anatol were escorted out of the agency, sending CAPR shares down on Friday morning. Verdun was the FDA's key overseer of Capricor's application for approval of its Deramiocel drug.Capricor on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/317/capricor-therapeutics-announces-positive-4-year-data-from">announced</a> positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Last month, Capricor announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is now planned for mid-July.Capricor on Friday said that after four years of continuous treatment, Deramiocel-treated patients showed preservation of cardiac function, including Left Ventricular Ejection Fraction, which is a measurement of how well the left ventricle, the heart's main pumping chamber, is working.Treatment also continued to slow the progression of skeletal muscle disease, the company said, while adding that the findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time.CEO Linda Marbán said that the company is moving toward potential approval of the therapy, with several key regulatory steps now completed.“Our continued dialogue with the FDA remains on track with no evidence of any delays,” she said.On Stocktwits, retail sentiment around Capricor jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_10_35_01_AM_png_6034c09f71.webp" alt="CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that, although things don't look good, the new 4-year data from the study could ‘change things’ for Capricor.<stembedurl>https://stocktwits.com/MrMarB/message/618459744</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 33% this year but has more than doubled its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/uniswap-uni-fair-gas/chlxZJTRRPA">Uniswap Makes Fees Someone Else’s Problem</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.54	--	--	N/A
Q2 '25	-$0.48	-$0.57	-19.75%	MISSED
Q1 '25	-$0.32	-$0.53	-67.37%	MISSED
Q4 '24	-$0.17	-$0.16	5.88%	BEAT
Q3 '24	-$0.36	-$0.38	-6.05%	MISSED

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CAPR News

CAPR Capricor Therapeutics Inc